Stan B. Kaye

29.9k total citations · 10 hit papers
217 papers, 19.2k citations indexed

About

Stan B. Kaye is a scholar working on Oncology, Reproductive Medicine and Molecular Biology. According to data from OpenAlex, Stan B. Kaye has authored 217 papers receiving a total of 19.2k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Oncology, 84 papers in Reproductive Medicine and 57 papers in Molecular Biology. Recurrent topics in Stan B. Kaye's work include Ovarian cancer diagnosis and treatment (83 papers), Cancer Genomics and Diagnostics (34 papers) and Cancer Treatment and Pharmacology (32 papers). Stan B. Kaye is often cited by papers focused on Ovarian cancer diagnosis and treatment (83 papers), Cancer Genomics and Diagnostics (34 papers) and Cancer Treatment and Pharmacology (32 papers). Stan B. Kaye collaborates with scholars based in United Kingdom, United States and Netherlands. Stan B. Kaye's co-authors include Johann S. de Bono, Roshan Agarwal, Timothy A. Yap, Alan Ashworth, Andrew Tutt, James Carmichael, David S.P. Tan, Jan H.M. Schellens, Peter C.C. Fong and Helen Swaisland and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Stan B. Kaye

213 papers receiving 18.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

2009 2.7k citations Peter C.C. Fong, David S. Boss et al. profile →
Ovarian cancer: strategies for overcoming resistance to chemotherapy

2003 961 citations Roshan Agarwal, Stan B. Kaye profile →
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

2006 794 citations Mark J. Ratain, Tim Eisen et al. Journal of Clinical Oncology profile →
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

2010 745 citations Peter C.C. Fong, Timothy A. Yap et al. Journal of Clinical Oncology profile →
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types

2002 683 citations Hilary Calvert, Stan B. Kaye et al. Journal of Clinical Oncology profile →
Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

2008 666 citations Gerhardt Attard, Alison Reid et al. Journal of Clinical Oncology profile →
Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.

1999 574 citations Stan B. Kaye et al. profile →
Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay.

1989 534 citations Jane A. Plumb, Stan B. Kaye et al. profile →
A decade of clinical development of PARP inhibitors in perspective

2019 495 citations Joaquı́n Mateo, Christopher J. Lord et al. Annals of Oncology profile →
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research

2013 416 citations Emma Kipps, Stan B. Kaye et al. profile →

Peers

Countries citing papers authored by Stan B. Kaye

Since Specialization

Citations

This map shows the geographic impact of Stan B. Kaye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stan B. Kaye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stan B. Kaye more than expected).

Fields of papers citing papers by Stan B. Kaye

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stan B. Kaye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stan B. Kaye. The network helps show where Stan B. Kaye may publish in the future.

Co-authorship network of co-authors of Stan B. Kaye

This figure shows the co-authorship network connecting the top 25 collaborators of Stan B. Kaye. A scholar is included among the top collaborators of Stan B. Kaye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stan B. Kaye. Stan B. Kaye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A decade of clinical development of PARP inhibitors in perspective breakdown → 2019 ·Annals of Oncology ·Joaquı́n Mateo, Christopher J. Lord, Violeta Serra, Andrew Tutt, Judith Balmañà, Marta Castroviejo‐Bermejo, Cristina Cruz, Ana Oaknin, Stan B. Kaye, Johann S. de Bono	495
2	Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers 2017 ·Cancer Discovery ·Johann S. de Bono, Ramesh K. Ramanathan, Lida A. Mina, Rashmi Chugh, John A. Glaspy, Saeed Rafii, Stan B. Kaye, Jasgit C. Sachdev, John V. Heymach, David C. Smith, Joshua W. Henshaw, Ashleigh Herriott, Miranda Patterson, Nicola J. Curtin, Lauren A. Byers, Zev A. Wainberg	314
3	Olaparib and somatic BRCA mutations 2017 ·Oncotarget ·Angela George, Susana Banerjee, Stan B. Kaye	9
4	Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation 2016 ·Molecular Cancer Therapeutics ·Joo Ern Ang, (unknown), (unknown), Yasmin J. Asad, Alan T. Henley, Melanie Valenti, Gary Box, Alexis de Haven Brandon, Richard D. Baird, Lori S. Friedman, Mika K. Derynck, Bart Vanhaesebroeck, Suzanne A. Eccles, Stan B. Kaye, Paul Workman, Johann S. de Bono, Florence I. Raynaud	16
5	Venous thromboembolism at time of diagnosis of ovarian cancer: Survival differs in symptomatic and asymptomatic cases 2015 ·Thrombosis Research ·(unknown), Heleen J. van Beekhuizen, Vivek Nama, (unknown), Marielle Nobbenhuis, Thomas Ind, S.A. Sohaib, F. Lofts, Sue Heenan, Martin Gore, Susana Banerjee, Stan B. Kaye, Desmond P.J. Barton	14
6	Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors 2014 ·Clinical Cancer Research ·Robin L. Jones, Edward S. Kim, Pilar Nava-Parada, Salma Alam, Faye M. Johnson, Andrew Stephens, Ronit Simantov, Srinivasu Poondru, (unknown), Scott M. Lippman, Stan B. Kaye, Craig P. Carden	77
7	Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study 2014 ·Clinical Cancer Research ·Víctor Moreno, David Olmos, Carlos Gomez‐Roca, Philippe A. Cassier, Rafael Morales‐Barrera, (unknown), Elisa Gallerani, André T. Brunetto, Patrick Schöffski, Silvia Marsoni, Jan H.M. Schellens, Nicolas Penel, Emile E. Voest, Jeffrey Evans, Ruth Plummer, Richard H. Wilson, Jean Charles Soria, Josep Tabernero, Jaap Verweij, Stan B. Kaye	14
8	Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey 2014 ·European Journal of Cancer ·Xavier Paolettí, Christophe Le Tourneau, Jaap Verweij, Lillian L. Siu, Lesley Seymour, Sophie Postel‐Vinay, Laurence Collette, Elisa Rizzo, S. Percy Ivy, David Olmos, Christophe Massard, Denis Lacombe, Stan B. Kaye, Jean‐Charles Soria	60
9	A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer 2014 ·British Journal of Cancer ·Rosalind Glasspool, Robert Brown, Martin Gore, Gordon Rustin, Iain A. McNeish, Richard H. Wilson, (unknown), James Paul, Melanie Mackean, Geoff Hall, Hani Gabra, Sarah Halford, Julie Walker, Kim Appleton, (unknown), Stan B. Kaye	84
10	The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer 2012 ·Molecular Cancer Therapeutics ·Craig P. Carden, Adam Stewart, (unknown), Emma Kipps, Lorna Pope, Mateus Crespo, Susana Miranda, Gerhardt Attard, Michelle D. Garrett, Paul A. Clarke, Paul Workman, Johann S. de Bono, Martin Gore, Stan B. Kaye, Udai Banerji	81
11	Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer 2011 ·Journal of Clinical Oncology ·Stan B. Kaye, Jan Lubiński, Ursula A. Matulonis, Joo Ern Ang, Charlie Gourley, Beth Y. Karlan, Amnon Amit, Katherine M. Bell‐McGuinn, Lee-may Chen, Michael Friedländer, Tamar Safra, Ignace Vergote, Mark Wickens, Elizabeth Lowe, James Carmichael, Bella Kaufman	378
12	Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials 2011 ·Clinical Cancer Research ·David Olmos, Richard D. Baird, Timothy A. Yap, Christophe Massard, Lorna Pope, Shahneen Sandhu, Gerhardt Attard, Juliet Dukes, Dionysis Papadatos-Pastos, (unknown), Stan B. Kaye, Johann S. de Bono	21
13	The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer 2010 ·Clinical Cancer Research ·Udai Banerji, D. Ross Camidge, Henk M.W. Verheul, Roshan Agarwal, Debashis Sarker, Stan B. Kaye, Ingrid M.E. Desar, Johanna N.H. Timmer-Bonte, Sabine Eckhardt, Karl D. Lewis, Kathryn H. Brown, Mireille Cantarini, Clive Morris, (unknown), Paul D. Smith, Carla M.L. van Herpen	176
14	Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval breakdown → 2010 ·Journal of Clinical Oncology ·Peter C.C. Fong, Timothy A. Yap, David S. Boss, Craig P. Carden, Marja Mergui‐Roelvink, Charlie Gourley, Jacques De Grève, Jan Lubiński, Susan Shanley, Christina Messiou, Roger A’Hern, Andrew Tutt, Alan Ashworth, John Stone, James Carmichael, Jan H.M. Schellens, Johann S. de Bono, Stan B. Kaye	745
15	Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors 2009 ·Molecular Cancer Therapeutics ·Richard D. Baird, Jos Kitzen, Paul A. Clarke, André Planting, (unknown), Alison Reid, (unknown), Luis López Lázaro, Begoña de las Heras, Ian Judson, Stan B. Kaye, Ferry A.L.M. Eskens, Paul Workman, Johann S. de Bono, Jaap Verweij	33
16	Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven breakdown → 2008 ·Journal of Clinical Oncology ·Gerhardt Attard, Alison Reid, Timothy A. Yap, Florence I. Raynaud, Mitch Dowsett, S. Settatree, Mary Barrett, Christopher Parker, Vanessa Martins, Elizabeth Folkerd, J. W. Clark, Colin S. Cooper, Stan B. Kaye, David P. Dearnaley, Gloria Lee, Johann S. de Bono	666
17	The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo 2007 ·Molecular Cancer Therapeutics ·Lesley‐Ann Martin, Julia E. Head, Sunil Pancholi, Janine Salter, Emma M. Quinn, Simone Detre, Stan B. Kaye, Angela Howes, Mitch Dowsett, Stephen Johnston	37
18	Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers 2007 ·Clinical Cancer Research ·Ruth Plummer, Gerhardt Attard, Simon Pacey, (unknown), Albiruni R. Abdul Razak, Rebecca M. Perrett, Mary Barrett, Ian Judson, Stan B. Kaye, Norma Lynn Fox, Wendy Halpern, A. Corey, Hilary Calvert, Johann S. de Bono	198
19	Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma breakdown → 2006 ·Journal of Clinical Oncology ·Mark J. Ratain, Tim Eisen, Walter M. Stadler, Keith T. Flaherty, Stan B. Kaye, Gary L. Rosner, Martin Gore, Apurva A. Desai, Amita Patnaik, Henry Q. Xiong, Eric K. Rowinsky, James L. Abbruzzese, Chenghua Xia, Ronit Simantov, Brian Schwartz, Peter J. O’Dwyer	794
20	Pharmacodynamic effects in patients treated with 6 hour infusion of the demethylating agent 5-aza-2 ' deoxycytidine (decitabine) 2005 ·ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) ·Robert Brown, Kim Appleton, Jane A. Plumb, Carol McCormick, (unknown), Sophie Barrett, Adrian Tang, (unknown), Stan B. Kaye, I. Judson, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact